PRKAA1 and obesity due to melanocortin 4 receptor deficiency: Due to its involvement in the regulation of a variety of metabolic processes and its central role in glucose and lipid homeostasis, AMPK has become an attractive drug target for the treatment of obesity, T2D, fatty liver disease, cancer, and other metabolic diseases [11], [16]–[18].